Say YES to HOPE

20 hours ago

💙 MARCH 13th IS NATIONAL METASTATIC COLORECTAL CANCER AWARENESS DAYEvery patient diagnosed with metastatic colorectal cancer deserves access to a multidisciplinary treatment plan, expert care, and HOPE.Metastatic colorectal cancer is different.It requires:✔ Expert multidisciplinary care✔ Access to biomarker testing✔ Knowledge of clinical trial options✔ Personalized treatment strategies✔ Emotional + peer support🐝 Awareness Helps Patients:🐝 Navigate complex treatment decisions🐝 Connect with expert specialists🐝 Find clinical trials faster🐝 Build personalized care roadmaps🐝 Never walk the metastatic journey alone📢 Join Us in Raising AwarenessTogether, we can improve outcomes and bring hope to metastatic colorectal cancer patients everywhere.👉 Learn More👉 Share Awareness👉 Support Patientswww.SayYesToHope.org🤝 PARTNER / SPONSOR Join us in amplifying Metastatic Colorectal Cancer Awareness!💙 #metastaticcrc#SayYEStoHope#HopeInTheFight#march13awareness #march13thisnationalmetastaticcolorectalcancerawarenessday #ImprovedOutcomes #TogetherWeWin ... See MoreSee Less

Photo

View on Facebook

Say YES to HOPE

1 day ago

March is Colorectal Cancer Awareness Month!Megan Hodges was diagnosed with metastatic colorectal cancer almost 22 years ago, at a time when long term survivorship wasn't the norm. She had a multidisciplinary team who offered options that saved her life.She is alive and healthy today, paving the way for other survivo#marchiscolorectalcanceraearenessmonthm#colorectalcancera#metastaticcancera#ifcancerspreadsr#multidisciplinaryi#PersonalizedTreatmentt#ittakesateama#Y90 #livermetastasest#interventionalradiologyo#MedicalOncologisto#radiationoncologyo#surgicaloncologisto#hepatologisto#GeneticTestings#Biomarkersrkers ... See MoreSee Less

Photo

View on Facebook

Say YES to HOPE

1 day ago

The U.S. Food and Drug Administration has recently approved zongertinib (Hernexeos) as a first‑line treatment for a specific subtype of non‑small cell lung cancer (NSCLC) with a rare genetic mutation. This means newly diagnosed patients with this mutation may now have a more effective, targeted therapy option earlier in their treatment journey. Tumor shrinkage rates were notably higher compared with standard therapies in clinical studies.www.reuters.com/business/healthcare-pharmaceuticals/us-fda-gives-full-approval-boehringers-lung-c...Boehringer Ingelheim #AdvocacyInAction #AwarenessMatters #MissionMonday #MetastaticMatters #patienteducation #SupportMatters #metastaticcancer #lcsm #coloncancer #SayYEStoHope #research #cancernews ... See MoreSee Less

US FDA approves first-line use of Boehringer Ingelheim's lung cancer drug

www.reuters.com

The U.S. Food and Drug Administration on Thursday approved Boehringer Ingelheim's zongertinib as a first-line treatment for a rare form of non-small cell lung cancer, making it the second drug to be c...

View on Facebook